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Background: Prompt Mental Health Care (PMHC, Norwegian adaption of Improving
Access to Psychological Therapies) has shown effects on symptoms of anxiety and
depression compared to treatment as usual (TAU). In this secondary analysis, we
examine the effectiveness of PMHC among clients presenting with symptoms of
social anxiety disorder (SAD) and/or agoraphobia on core symptoms at 6‐ and 12‐
month follow‐up.
Methods: Randomized controlled trial in two PMHC sites (70:30 ratio PMHC:TAU).
Of participants, 61.3% (n = 472) scored at caseness for SAD and 47.7% (n = 367) for
agoraphobia (40% both). Effects on SAD avoidance and physiological discomfort
(SPIN‐9), SAD cognitions (ATQ‐SA), agoraphobic avoidance (MIA‐8), and agor-
aphobic cognitions (ATQ‐AP) were examined in piecewise growth models.
Results: The PMHC group showed substantially greater symptom reduction than the
TAU group for all outcomes: At 6‐month follow‐up, the between‐group effect sizes
were d −0.60 (95% CI: −0.94 to −0.26) for SPIN‐9, −0.45 (95% CI: −0.70 to −0.20) for
ATQ‐SA, −0.50 (95% CI: −0.87 to −0.13) for MIA‐8, and −0.61 (95% CI: −0.92 to
−0.31) for ATQ‐AP. All effects were sustained at similar level at a 12‐month
follow‐up.
Conclusion: PMHC effectively alleviated SAD and agoraphobia symptoms, and in-
dividuals struggling with such symptoms constituted a large proportion of clients.
Although results should be interpreted with caution due to risk of attrition bias, they
lend further support for a scale‐up of PMHC and similar initiatives. Individuals
struggling with SAD and/or agoraphobia stood out as relatively high burdened,
whereas only one of five had sought help the last 12 months, underscoring the need
for the PMHC service.
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1 | INTRODUCTION
Social anxiety disorder (SAD) and agoraphobia are two of the most
common and disabling anxiety disorders. Their large negative impacts
are related to high prevalence (Lecrubier et al., 2000; Remes et al.,
2016; D. J. Stein et al., 2017) and early onset (Jones, 2018; Kessler
et al., 2007), but also by their wide‐ranging associated impairment
across several life domains, such as sleep, social/romantic relations,
and occupational life (Aderka et al., 2012; Fehm et al., 2008;
Lecrubier et al., 2000; M. B. Stein & Kean, 2000; D. J. Stein et al.,
2017; Stuhldreher et al., 2014; Wittchen & Beloch, 1996), seen both
in diagnostic threshold and subthreshold cases (Fehm et al., 2008).
Moreover, both are associated with an elevated risk of developing
other disorders, such as depression and alcohol/substance depen-
dence (Lecrubier et al., 2000) and to follow a chronic course if left
untreated (Bruce et al., 2005; Steinert et al., 2013; Wittchen &
Beloch, 1996). Agoraphobia often occurs comorbid to panic disorder
(Goisman et al., 1995), and these were conceptually linked in DSM‐IV
whilst are coded separately in DSM‐5 (Center for Behavioral Health
Statistics and Quality, 2016). Despite their massive costs, both for
the individual and society, anxiety disorders are often undetected in
primary care (Kroenke et al., 2007) if at all seen, as individuals with
SAD, in particular, tend to avoid seeking help (Lecrubier et al., 2000).
Prompt Mental Health Care (PMHC) is the Norwegian adapta-
tion of the English “Increasing Access to Psychological Therapies”
(IAPT), both innovative initiatives to improve access to primary care
treatment for persons with symptoms of mild‐to‐moderate depres-
sion and anxiety disorders, including SAD and agoraphobia. Key
features to enable large‐scale roll‐out and ensure broad and prompt
access (in PMHC within 48 h), are the offering of more low‐intensity
treatments (guided self‐help and psycho‐educative courses) and
training of new therapists (1‐year training). PMHC treatments are
based on cognitive‐behavioral therapy (CBT). The service should
supplement existing services, be free of charge, and without need for
referral (see Lervik et al., 2020 for more details).
Although IAPT and PMHC were evaluated positively in several
studies (Knapstad et al., 2018; Myrtveit et al., 2019), one common
critique was that the available evidence was not based on studies
using a randomized controlled trial (RCT) design. Both among re-
searchers and policymakers, the idea persists that people with
mild‐to‐moderate anxiety and depression may not need treatment
(D. M. Clark et al., 2009; Shepardson et al., 2018). These aspects
were important reasons for conducting an RCT in Norway, com-
paring PMHC to treatment as usual (TAU). Primary and secondary
outcomes from this trial are previously reported, finding PMHC
more effective than TAU (Knapstad et al., 2020), including sus-
tained effects at 12‐month follow‐up (Sæther et al., 2020). The
treatment effect for individuals struggling with specific anxiety
problems, such as social anxiety or agoraphobia, is yet to be ad-
dressed. The single group evaluation of the 12 first PMHC pilots
promisingly showed medium to large pre‐post improvement in
symptoms of both SAD (SPIN‐9, d = −0.6) and agoraphobia (MIA‐8,
d = −0.8). These findings are, however, hampered by the lack of a
control group and a modest participation rate (overall 65%). Long‐
term effects are also unknown.
CBT is considered to be the first‐line treatment for both SAD
and agoraphobia (Bandelow et al., 2015; Carpenter et al., 2018; Hans
& Hiller, 2013; Hofmann et al., 2012; Mayo‐Wilson et al., 2014).
Treatment effects and magnitude of effects are, however, still un-
certain. First, only a few high‐quality trials have been conducted and
these show lower effect sizes than low‐quality studies for both SAD
and agoraphobia (Cuijpers et al., 2016). Second, most trials have used
waitlist control groups, which also gain higher effect sizes than other
control modes (Cuijpers et al., 2016). In sum, Cuijpers et al. (2016) did
not find enough high‐quality studies to evaluate the effect of CBT
compared to TAU for SAD in a 2016 review. Additionally, some
evidence indicate that treatment effects are somewhat lower for
SAD and panic disorder with agoraphobia than many other anxiety
disorders (Carpenter et al., 2018) and agoraphobic avoidance is
found to be the most consistent predictor of poor treatment re-
sponse in CBT for panic disorders and agoraphobia (Porter &
Chambless, 2015). Notably, also in an IAPT context, presenting with
SAD or agoraphobia as a comorbid problem predicted poor treat-
ment response (McDevitt‐Petrovic et al., 2019).
The objective in the current study is thus to do secondary ana-
lyses of the PMHC trial to investigate the effectiveness of the PMHC
treatment compared to TAU among clients presenting with symp-
toms of SAD and/or agoraphobia on core symptoms at 6‐ and 12‐
month follow‐up. More specifically, the outcomes of interest are SAD
avoidance and physiological discomfort, SAD cognitions, agoraphobic
avoidance, and agoraphobic cognitions. We will also examine the
characteristics of clients presenting with symptoms of SAD and/or
agoraphobia as compared to PMHC clients in total.
2 | MATERIALS AND METHODS
The trial was reported according to the CONSORT statement and
is registered at ClinicalTrials.gov (NCT03238872). No changes to
the design were made after trial commencement. The trial
protocol was approved by the Regional ethics committee for
Western Norway (REK‐vest no. 2015/885). The outcomes in the
present study (social anxiety, agoraphobia) were not pre-
registered in the trial protocol. Details about the trial design are
provided in the primary evaluation (Knapstad et al., 2020) and
summarized in the following.
2.1 | Recruitment and selection procedures
The trial was conducted within routine care in two municipalities;
Kristiansand and Sandnes. Eligibility criteria were anxiety and/or
mild‐to‐moderate depression (PHQ‐9 ≥ 10 and/or GAD‐7 ≥ 8, no
formal diagnosis provided), being ≥18 years old, residing in
Kristiansand or Sandnes, and having basic Norwegian language
proficiency. Clients were excluded if they were entitled to
2 | KNAPSTAD AND SMITH
secondary healthcare due to suicide risk, eating disorder, bipolar
disorder, severe depression, incapacitating anxiety, psychotic
symptoms, severe substance abuse, or personality disorder. Ad-
ditional exclusion criteria during the trial were having a serious
physical health problem or two or more previous treatment at-
tempts without effect. Excluded clients were referred to their GP
or other relevant services.
Those contacting PMHC in Sandnes and Kristiansand got an
appointment for individual assessment at the PMHC clinic. A
therapist conducted a clinical interview, provided information
about the trial and PMHC treatment. Eligible clients agreeing to
participate gave written consent and registered to a secure on-
line data‐portal used for administrative purposes, to randomize
eligible clients, and to collect all questionnaire data from both
clients and therapists.
2.2 | Trial design and randomization
A randomized controlled superiority design with parallel assign-
ment was used. The participants were randomized (using a com-
puterized random number generator) on a 70:30 ratio (PMHC vs.
TAU) with simple randomization within each of the two sites and
no further constraints. Participants allocated to PMHC were in-
formed by a member of the PMHC team, whilst the TAU group
were informed through a standardized letter sent by the project
coordinator.
2.3 | Interventions
A summary of interventions follows, we refer to the primary eva-
luation for further details (Knapstad et al., 2020; Lervik et al., 2020).
2.3.1 | Prompt Mental Health Care
A matched‐care model organized care, where both initial assessment
and client preferences informed choice of treatment, notably with
low‐intensity treatments as recommended first choice. At both trial
sites, most clients started with a four‐session psychoeducational
course. Guided self‐help programs were to a little extent readily
available during most of the trial period. Individual CBT was framed
to 2–15 sessions. Treatment type and length did not differ sig-
nificantly between those scoring above and below the clinical
threshold for SAD/agoraphobia (all p > .05). The whole PMHC group
received median 5 (IQR = 4–9) treatment sessions. In total, 85.8%
received at least two treatment sessions (ex. assessment) and 76.9%
completed treatment (therapist reporting that treatment goal was
fulfilled and/or completed at least six sessions). Group‐based psy-
choeducation was the primary treatment form for 35.1%, individual
CBT for 30.0%, and guided self‐help for 0.9%. The remaining 34.0%
received a combination of these treatment forms.
2.3.2 | Treatment as usual
This included all ordinary services available to the target population.
This often included follow‐up by the GP, alternatively by private
psychologists or occupational health services. The letter informing
TAU clients about their allocation, also encouraged clients to contact
their GP for further follow‐up, and provided references to publicly
available self‐help resources (Internet, books).
As previously reported (Sæther et al., 2020), about one in four
reported at a 12‐month follow‐up to have received some form of
additional treatment in the PMHC group since baseline, while this
was one in two in the TAU group. The additional treatment was
mainly provided by GP's and/or specialist mental healthcare (Sæther
et al., 2020). These patterns were similar for the subgroups of clients
with clinically significant baseline levels of social anxiety and agor-
aphobia. As such, the TAU condition reflected, as intended, the si-
tuation before the arrival of PMHC.
2.4 | Measures
In the present study, we used data collected at baseline, 3, 6, and 12
months after baseline in both the PMHC and TAU groups.
2.4.1 | SAD avoidance and physiological discomfort
An abbreviated form of the widely used Social Phobia Inventory
(Connor et al., 2000), SPIN‐9, was employed, whereof five items re-
gard avoidance (e.g., being in the center of attention, going to parties)
and four physiological discomfort (e.g., blushing, trembling).
Responses were given on a five‐point scale (“not at all” (1) to
“extremely” (5) bothered the past week).
2.4.2 | Agoraphobic avoidance
We used an abbreviated version of the Mobile Inventory for Agor-
aphobia (Chambless et al., 1985), MI‐9, suggested from generalizability
study carried out at Modum bad (Hoffart et al., 2018). The clients rated
avoidance due to anxiety or discomfort of nine places/situations, both
when alone and when accompanied by a trusted companion, on a five‐
point scale ranging from “never” (1) to “always” (5).
2.4.3 | SAD cognitions and agoraphobic cognitions
We employed items from the Anxious Thoughts Questionnaire
(ATQ) relating to social anxiety (ATQ‐SA) and agoraphobia (ATQ‐
AP). ATQ‐SA contains four items from the social probability and
cost questionnaire (McManus et al., 2000), selected on the basis
of their high Cronbach's α (Hoffart et al., 2009). ATQ‐AP contains
three items concerning physical catastrophes and four
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concerning loss of control catastrophes from the agoraphobic
cognitions questionnaire (Chambless et al., 1984), selected based
on Cronbach's α and frequent endorsement in a study among
patients considering agoraphobia their main problem (Hoffart,
1995). Responses were given on a scale from 0 (not at all agree)
to 100 (totally agree), recoded to 1–11, giving a sum score of
4–44 for ATQ‐SA 7‐77 for ATQ‐AP.
2.5 | Analyses
Stata version 15 was used to generate descriptive statistics. To
examine the effects of PMHC on the SAD and agoraphobia out-
comes, their continuous scores were modeled by means of pie-
cewise growth models in Mplus v. 8.2, in which fixed slopes were
estimated for the intervals baseline to 6 months, and baseline to
12 months. For the SAD outcomes, only clients with clinically
significant levels of SAD were included as defined by a SPIN‐9
score more than 18 (N = 472; Connor et al., 2000; IAPT Data
Handbook, 2011). For the agoraphobia outcomes, only clients
with clinically significant levels of agoraphobia were included as
defined by an MI‐9 score ≥1.61 (N = 367; Chambless et al., 2011).
Site (Kristiansand vs. Sandnes) and group (PHMC vs. TAU) were
included as fixed effects in all models. Between‐group effect sizes
(d) were calculated by dividing the mean difference in estimated
change scores from baseline to 6‐ and 12‐month follow‐up by the
standard deviation at baseline. Robust maximum likelihood was
used as an estimator, providing unbiased estimates under the
assumption of data missing at random (Enders, 2010).
3 | RESULTS
3.1 | Participant flow and baseline data
As previously described (Knapstad et al., 2020), 1188 clients were
assessed for eligibility between November 9, 2015 and August 31,
2017. Of these, 774 (92.7% of eligible) were randomized, 26 declined
trial participation, 35 treatment. In total, 526 (68.0%) clients were
allocated to PMHC and 248 (32.0%) to TAU. Four TAU participants
requested full withdrawal, giving a net allocation of 244 to TAU. As
shown in the primary evaluation, demographic and clinical char-
acteristics were balanced between the groups at baseline (Knapstad
et al., 2020).
Of the participants, 61.3% (n = 321 in PMHC and n = 151 in TAU)
scored at caseness SAD and 47.7% (n = 247 in PMHC and n = 120 in
TAU) for agoraphobia at baseline. There was a substantial overlap
between these groups; 65.3% of the SAD cases also scored at case-
ness for agoraphobia, and 83.9% vice versa (40% both). The corre-
lation between the outcome measures was moderate to strong
(Table 1). However, there was a maximum of 40.1% overlap between
variables (SPIN‐9 and ATO‐SA), clearly indicating that they measured
separate constructs.
Table 2 displays baseline demographic and clinical characteristics
of the total sample and participants scoring at caseness for SAD and
agoraphobia, respectively. There were several statistically significant
differences between clients above and below clinical cutoff, albeit of
small magnitude. For both the SAD and agoraphobia groups, the
following characteristics stood out: fewer had higher education and
were in regular work, and they had a higher mean score of symptoms
of anxiety (GAD‐7) and depression (PHQ‐9; Table 2). The agor-
aphobia group also included a higher percentage of women than the
remaining clients.
3.2 | Outcomes
Data collections for 6‐ and 12‐month follow‐up were finalized by
March 2018 and September 2018, respectively. Slightly more out-
come data were available in the PMHC than the TAU group (60 vs.
45% data available at 6 months and 51 vs. 39% at 12 months). We
refer to the main outcome papers for a detailed evaluation of loss to
follow‐up (Knapstad et al., 2020; Sæther et al., 2020). Shortly, missing
data were associated with some individual characteristics, such as
age and baseline PHQ score, though with modest effect sizes. The
correlations between outcome and these variables were mostly
weak, which reduced the possibility to correct for bias in case of
missing not at random.
Overall, the PMHC group showed substantially more symp-
tom reduction than the TAU group between baseline and
6‐month follow‐up for all four outcomes. Furthermore, symptom
levels remained rather stable from 6 to 12 months as did
between‐group effect sizes at 12‐month follow‐up for all out-
comes. Symptom score changes and between‐groups effect sizes
per outcome are detailed in Table 3.
3.2.1 | Change in SAD avoidance and physiological
symptoms (SPIN‐9) and SAD cognitions (ATQ‐SA)
from baseline to 6 and 12 months
Among those scoring at caseness for SAD according to SPIN‐9
(n = 472), the estimated SPIN score changed from 26.48 at baseline
TABLE 1 Correlation (Pearson's r) between continuous outcomes
at baseline
SPIN‐9 MIA‐8 ATQ‐SA ATQ‐AP
SPIN‐9 1.00
MIA‐8 0.54 1.00
ATQ‐SA 0.64 0.39 1.00
ATQ‐AP 0.40 0.39 0.58 1.00
Note: All correlations significant at a p < .001 level.
Abbreviations: ATQ‐AP, Anxious Thoughts Questionnaire−Agoraphobia;
ATQ‐SA, Anxious Thoughts Questionnaire‐Social Anxiety; MIA‐8, Mobile
Inventory for Agoraphobia‐8; SPIN‐9, Social Phobia Inventory‐9.
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to 19.84 at 6 months in the PMHC group, and 26.94 to 23.10 in TAU
(Table 3). This equaled a between‐group effect size of d −0.60 (95%
CI: −0.94 to −0.26, p = .001). The change from 6 to 12 months did not
differ between PMHC and TAU (Wald test: 0.087, df = 1, p = .768),
and the between‐group effect size of change from baseline to
12‐month follow‐up was d −0.55 (95%CI: −0.95 to −0.14, p = .008).
For SAD cognitions, there was a mean score difference at
6‐month follow‐up of −5.24 (95%CI: −8.17 to −2.31) and a
between‐group effect size of −0.45 (95% CI: −0.70 to −0.20,
p < .001), both in favor of PMHC (Table 3). At 12 months, the
mean difference remained similar at −5.74 (95% CI: −9.03 to
−2.46) and the between‐group effect size was −0.49 (95% CI:
−0.77 to −0.21, p = .001). Again, there was no difference in change
in symptoms from 6 to 12 months between PMHC and TAU (Wald
test: 0.124, df = 1, p = .725).
3.2.2 | Change in agoraphobic avoidance (MIA‐8)
and agoraphobic cognitions (ATQ‐AP) from baseline
to 6 and 12 months
Among those scoring above the clinical threshold for agoraphobia
(n = 367), the estimated MIA‐8 score changed from 41.68 at
baseline to 29.95 at 6 months in PMHC and 42.70–35.74 in TAU,
giving a between‐group Cohen's d of −0.50 (95% CI: −0.87 to
−0.13, p = .008). In both groups, the symptom level remained ra-
ther stable from 6 to 12 months, with no difference in degree of
change (Wald test: 0.429, df = 1, p = .513). The between‐group
effect size at 12 months was −0.62 (95% CI: −0.98 to −0.26,
p = .001; Table 3).
Finally, the estimated agoraphobic cognitions score changed
from 26.64 at baseline to 15.83 at 6 months in PMHC and
26.69–25.00 in TAU, giving a between‐group effect size of −0.61
(95% CI: −0.92 to −0.31, p < .001). The change from 6 to 12 months
follow‐up did not differ between PMHC and TAU (Wald test: 0.00,
df = 1, p = .991), and between‐group effect size at 12 months re-
mained at −0.61 (95% CI: −0.93 to −0.30, p < .001).
4 | DISCUSSION
4.1 | Main findings
In this pragmatic RCT trial of PMHC, 61.3% of clients had clinical
levels of SAD and 47.7% agoraphobia at baseline (40% both).
Among these, the PMHC treatment group showed substantially
more improvement on core symptoms at both 6‐ and 12‐month
follow‐up than the TAU group. More specifically, close to medium
and medium between‐group effect sizes (Cohen's d range: −0.45
to −0.61) were found for SAD avoidance and physiological dis-
comfort, SAD catastrophic cognitions, agoraphobic avoidance,
and agoraphobic catastrophic cognitions. These treatment effects
were sustained and did not change from 6 to 12 months
follow‐up.




in total (n = 770)
Social anxiety
disordera (n = 472)
Agoraphobiaa
(n = 367)
Mean (SD) age (years) 35.0 (12.2) 34.0 (12.2)** 33.9 (12.7)*
Women 66.0 (508) 67.2 (317) 73.8 (271)***
Higher education 42.5 (324) 34.3 (160)*** 31.6 (115)***
Having a partner 57.3 (438) 54.4 (254)* 52.6 (191)*
Being in regular work 37.5 (289) 31.8 (150)*** 30.3 (111)***
Immigration background 11.1 (85) 11.3 (53) 11.2 (41)
Anxiety severity, Mean GAD score (SD) 11.2 (4.6) 12.2 (4.3)*** 12.5 (4.2)***
Depression severity, Mean PHQ score (SD) 13.9 (5.0) 15.1 (4.8)*** 15.2 (4.9)***
Weekly use of anxiolytic medication 6.1 (47) 6.7 (31) 7.4 (27)
Daily use of antidepressants 13.6 (104) 16.0 (75)* 16.0 (58)
Weekly use of sleep medication 15.0 (115) 17.7 (83)** 16.3 (59)
Having elevated symptoms ≥6 months before baseline 86.9 (667) 88.8 (419)* 89.4 (328)*
Having symptoms at baseline level ≥6 months before baseline 65.6 (499) 69.3 (322)** 70.3 (255)*
Sought help for similar problems during the last 12 months
before baseline
20.8 (160) 21.2 (100) 22.1 (81)
Note: The descriptive statistics represent percentages (numbers) unless stated otherwise, cases are compared to noncases. *p < .05, **p < .01, ***p < .001.
Abbreviations: GAD, generalized anxiety disorder; PHQ, Patient Health Questionnaire; PMHC, Prompt Mental Health Care; SD, standard deviation.
aDifferences between clients above and below clinical cutoff compared using χ2 tests and two‐sample t tests.
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4.2 | Interpretation
The treatment effects found are solid and particularly encouraging in
light of the short‐term treatment (median 5 sessions) and frequent
use of group‐based psychoeducation (35% this format only) provided
in the PMHC group. As mentioned in Section 1, albeit a range of
studies has shown effect of CBT for anxiety disorders, including SAD
and agoraphobia, fewer have been conducted in primary care set-
tings and included long‐term follow‐up. Especially it is questioned
whether short‐term care is able to sustain improvement over time
(A. Clark et al., 2018; Hollon et al., 2002; Vittengl et al., 2007), and
the lack of systematic follow‐up routines is mentioned as one of the
current limitations in IAPT (D. M. Clark, 2018).
The magnitude of effects is comparable to CBT trials for SAD
and agoraphobia using TAU control groups, which in meta‐analyses
are reported to be of small to medium size (Acarturk et al., 2008;
Cuijpers et al., 2016). A meta‐analysis of multimodal CBT for anxiety
and depression in primary care, thus similar to the PMCH setting,
gave a medium effect size (d = 0.46) for anxiety symptoms when
compared to TAU. Separate results for social anxiety and agor-
aphobia were, however, not provided, and follow‐up time was only a
medium of four months. A recent, comprehensive meta‐analysis fo-
cusing on long‐term effects found small to medium effect sizes across
control conditions for SAD both between 6 and 12 months (Hedges
g = 0.34) and ≥12 months follow‐up (g = 0.42). For panic disorder with
or without agoraphobia, however, CBT was only found superior when
compared to pill placebo, and only at 6 to 12 months follow‐up (van
Dis et al., 2020). Notably, as these were studies of patients having
received a formal diagnosis, and mostly following traditional face‐to‐
face CBT, the findings are not directly comparable to those from the
present study.
Individuals struggling with SAD and/or agoraphobia constituted
a large proportion of clients in this trial. This was similarly found in a
sample of clients awaiting treatment within an IAPT service, where
48% met criteria for a MINI agoraphobia diagnosis and 22/11% with
a generalized/nongeneralized social phobia (Hepgul et al., 2016).
Moreover, the socioeconomic characteristics of those above the
clinical cutoff in the current trial mirrored epidemiological studies,
for instance, finding SAD to be associated with younger age, female
gender, and lower education (D. J. Stein et al., 2017). These results
may indicate that PMHC succeeds in reaching out to and is well
received in this group of clients. This is generally important, as
viable scale‐up of treatment programs not only depends on offering
effective treatment but also reaching those in greatest need (Jorm
et al., 2017). For SAD and agoraphobia, this is particularly relevant,
as individuals struggling with SAD tend to avoid seeking help or talk
about their problems (Lecrubier et al., 2000), and make fewer pri-
mary care visits compared to individuals with other mental dis-
orders (Gross et al., 2005). In addition, their problems often go
unrecognized in primary care (Kroenke et al., 2007). It can be
speculated that services like PMHC, which focus on the normal-
ization of mental health problems, may reduce the threshold of
seeking help. Taking efforts to further increase reach out will be
valuable both from a cost‐perspective and individual burden and
quality of life‐perspective (Stuhldreher et al., 2014). Notably, the
SAD and agoraphobia subgroups displayed moderate‐severe mean
PHQ9 baseline‐scores, possible indicating comorbidity. Comorbidity
can be regarded “a rule more than an exception” for these anxiety
problems, commonly depression in SAD (Lecrubier et al., 2000) and
panic disorder in agoraphobia (Goisman et al., 1995), and is asso-
ciated with a higher overall burden. As the study was conducted in a
real life‐primary care setting and included a heterogeneous popu-
lation, not formally diagnosed, the results might not be specific to
SAD/agoraphobia, but more general to individuals experiencing
anxious distress and possibly multiple problems or disorders. The
implications of the comorbidity between SAD and depression are
multiple (Koyuncu et al., 2019), but may most notably affect the
course and outcome of treatment. As such, the observed effects on
symptoms of SAD can be interpreted as reassuring.
The current NICE guideline recommendation is still to offer in-
dividual instead of group CBT in treatment of SAD, pointing to evi-
dence that the latter is less clinical‐ and cost‐effective (National
Institute of Health and Care Excellence, 2013). It is thus interesting
to observe that psychoeducational group‐courses were offered to
clients with SAD symptoms to the same extent as other clients in
PMHC, and that as many as one in three received this treatment
modality only. Psychoeducational groups in PMHC were employed
both as a mean to avoid waiting lists and therapeutically to foster
normalization of mental health problems. While we do not know to
what extent the observed effect of PMHC is driven by group treat-
ment, the findings are encouraging for the acceptability and clinical
effectiveness of psychoeducational groups among clients struggling
with SAD and agoraphobia. A large network meta‐analysis notably
found large effects for SAD of both individual and group CBT when
compared to wait‐list control, but only of individual CBT when
compared to psychological controls (Mayo‐Wilson et al., 2014).
Future studies should investigate how different treatment elements
within the context of PMHC (low intensity, high intensity, mixed)
contribute individually on symptoms of SAD and agoraphobia.
4.3 | Strengths and limitations
The current study responds well to the call for well‐powered RCTs
(van Dis et al., 2020; Imai et al., 2016; Porter & Chambless, 2015),
including ITT‐analyses (Carpenter et al., 2018) and long‐term follow‐
up (van Dis et al., 2020; Imai et al., 2016; Mayo‐Wilson et al., 2014).
The trial followed a strict protocol to secure control whilst following
routine care as closely as possible to maximize external validity. We
employed IAPT's recommended measures for SAD (SPIN) and agor-
aphobia (MI), respectively (D. M. Clark, 2018; National Institute of
Health and Care Excellence, 2013), which have solid psychometric
properties and facilitated comparisons with IAPT results.
The most important limitation to consider is the loss to follow‐
up, which is a common challenge in these kinds of studies (van Dis
et al., 2020). As the rate of missing outcome data was both
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substantial and not equal across treatment groups, this may have
introduced bias that could not be fully mitigated by the state‐of‐the‐
art missing data procedures used. Notably, modeling of IAPT data
showed that clients suffering with agoraphobia were less likely to
attend their appointments than those with other anxiety disorders
(Firth et al., 2020). In the current trial, such noncompliance could
provide bias if differential across the treatment arms. Though bias
cannot be fully excluded, several sensitivity analyses conducted in
the primary outcome paper indicated that accounting for differential
attrition and other missing data not‐at‐random scenarios did not
substantially alter the results (Knapstad et al., 2020).
The additional treatment outside PMHC, reported by about 25%
of participants in the PMHC group, may account for some of the
reported effectiveness of PMHC versus TAU. However, given the
randomization and that the majority did not receive additional
treatment, we expect this effect to be relatively small.
It should also be noted no formal diagnoses are set in PMHC and
that it is unclear to what extent the PMCH group received treatment
specifically for SAD or agoraphobia. The findings might thus be
particularly relevant to similar primary care settings.
5 | CONCLUSION
Individuals struggling with SAD and/or agoraphobia constituted a
large proportion of clients in this trial, which showed that the PMHC
treatment effectively alleviated SAD and agoraphobia symptoms
compared to TAU. Their socioeconomic characteristics mirrored the
picture from epidemiological studies, indicating that PMHC succeeds
in reaching out to and is well received in this group of clients. The
current results thus add to previous findings supporting a further
scale‐up of PMHC to narrow the treatment gap. A scale‐up can be
considered particularly valuable for individuals struggling with SAD
and/or agoraphobia, as they were relatively more burdened than the
remaining PMHC clients presented, displaying higher symptom se-
verity and less work participation.
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